Skip to main content
Erschienen in: Current Bladder Dysfunction Reports 4/2020

14.11.2020 | Neurogenic Bladder (C Powell, Section Editor)

The Evidence For and Against Prostate-Reducing Procedures for Men with Neurogenic Bladder

verfasst von: Timothy M. Han, Patrick J. Shenot, Alex Uhr, Lydia Glick, Akhil K. Das

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The evaluation of anatomic bladder outlet obstruction due to benign prostatic hyperplasia in patients with neurogenic bladder dysfunction can be a challenging and complex process for urologists. Lower urinary tract symptoms are non-specific, and the attribution of symptoms to underlying neurologic disease may result in withholding potentially beneficial therapies and procedures from patients with benign prostatic hyperplasia. Conversely, the underlying neurologic disorder may have profound effects on lower urinary tract symptoms and quality of life and must be considered in patient management decisions. Thorough evaluation is necessary to evaluate male patients with concomitant benign prostatic hyperplasia and neurogenic bladder with careful attention to the underlying neurologic disease. While surgical management of anatomic bladder outlet obstruction has a clear role in carefully selected and thoroughly evaluated patients with neurogenic bladder, treatment strategies must be individualized for each patient. This review seeks to explore the role of prostate-reducing surgeries in management of patients with neurogenic bladder and to compile evidence for and against these procedures in this population.

Recent Findings

Only a few studies have been published exploring prostate-reducing surgery in the management of patients with neurogenic bladder, with no recent trials. These existing studies are poorly controlled and are characterized by small, heterogeneous study populations, retrospective design, and high risk of bias.

Summary

While some studies suggest positive outcomes from prostate-reducing surgery for management of patients with neurogenic bladder, more high-quality trials are needed.
Literatur
1.
2.
Zurück zum Zitat Pannek J, Berges RR, Cubick G, Meindl R, Senge T. Prostate size and PSA serum levels in male patients with spinal cord injury. Urology. 2003;62(5):845–8.CrossRef Pannek J, Berges RR, Cubick G, Meindl R, Senge T. Prostate size and PSA serum levels in male patients with spinal cord injury. Urology. 2003;62(5):845–8.CrossRef
3.
Zurück zum Zitat Sakakibara R, Hamano S, Uchiyama T, Liu Z, Yamanishi T, Hattori T. Do BPH patients have neurogenic detrusor dysfunction? A uro-neurological assessment. Urol Int. 2005;74(1):44–50.CrossRef Sakakibara R, Hamano S, Uchiyama T, Liu Z, Yamanishi T, Hattori T. Do BPH patients have neurogenic detrusor dysfunction? A uro-neurological assessment. Urol Int. 2005;74(1):44–50.CrossRef
4.
Zurück zum Zitat Elsaesser E, Stoephasius E. Urological operations for improvement of bladder voiding in paraplegic patients. Paraplegia. 1972;10:68–77.PubMed Elsaesser E, Stoephasius E. Urological operations for improvement of bladder voiding in paraplegic patients. Paraplegia. 1972;10:68–77.PubMed
5.
Zurück zum Zitat Koyanagi T, Arikado K, Tsuji I. Radical transurethral resection of the prostate for neurogenic dysfunction of the bladder in male paraplegics. J Urol. 1981;125(4):521–7.CrossRef Koyanagi T, Arikado K, Tsuji I. Radical transurethral resection of the prostate for neurogenic dysfunction of the bladder in male paraplegics. J Urol. 1981;125(4):521–7.CrossRef
6.
Zurück zum Zitat Koyanagi T, Morita H, Takamatsu T, Taniguchi K, Shinno Y. Radical transurethral resection of the prostate in male paraplegics revisited: further clinical experience and urodynamic considerations for its effectiveness. J Urol. 1987;137(1):72–6.CrossRef Koyanagi T, Morita H, Takamatsu T, Taniguchi K, Shinno Y. Radical transurethral resection of the prostate in male paraplegics revisited: further clinical experience and urodynamic considerations for its effectiveness. J Urol. 1987;137(1):72–6.CrossRef
7.
Zurück zum Zitat Shinno Y. An electromyographic study of detrusor sphincter dyssynergia in neurogenic vesical dysfunction. Part 2. Changes after radical transurethral resection of prostate and response to alpha-adrenergic stimulation. Nihon Hinyokika Gakkai Zasshi. 1989;80(10):1443–50.PubMed Shinno Y. An electromyographic study of detrusor sphincter dyssynergia in neurogenic vesical dysfunction. Part 2. Changes after radical transurethral resection of prostate and response to alpha-adrenergic stimulation. Nihon Hinyokika Gakkai Zasshi. 1989;80(10):1443–50.PubMed
8.
Zurück zum Zitat Staskin DS, Vardi Y, Siroky MB. Post-prostatectomy continence in the parkinsonian patient: the significance of poor voluntary sphincter control. J Urol. 1988;140(1):117–8.CrossRef Staskin DS, Vardi Y, Siroky MB. Post-prostatectomy continence in the parkinsonian patient: the significance of poor voluntary sphincter control. J Urol. 1988;140(1):117–8.CrossRef
9.
Zurück zum Zitat Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999;163(1):94–8.CrossRef Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999;163(1):94–8.CrossRef
10.
Zurück zum Zitat Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol. 1994;151:1336–41.CrossRef Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol. 1994;151:1336–41.CrossRef
11.
Zurück zum Zitat • Sakakibara R, Panicker J, Simeoni S, et al. Bladder dysfunction as the initial presentation of multiple system atrophy: a prospective cohort study. Clin Auton Res. 2019;29(6):627–31 This study prospectively explored how often and how early bladder symptoms predate motor symptoms in multiple system atrophy.CrossRef • Sakakibara R, Panicker J, Simeoni S, et al. Bladder dysfunction as the initial presentation of multiple system atrophy: a prospective cohort study. Clin Auton Res. 2019;29(6):627–31 This study prospectively explored how often and how early bladder symptoms predate motor symptoms in multiple system atrophy.CrossRef
12.
Zurück zum Zitat Chandiramani VA, Palace J, Fowler CJ. How to recognize patients with parkinsonism who should not have urological surgery. Br J Urol. 1997;80(1):100–4.CrossRef Chandiramani VA, Palace J, Fowler CJ. How to recognize patients with parkinsonism who should not have urological surgery. Br J Urol. 1997;80(1):100–4.CrossRef
13.
Zurück zum Zitat Roth B, Studer UE, Fowler CJ, Kessler TM. Benign prostatic obstruction and Parkinson’s disease--should transurethral resection of the prostate be avoided? J Urol. 2009;181(5):2209–13.CrossRef Roth B, Studer UE, Fowler CJ, Kessler TM. Benign prostatic obstruction and Parkinson’s disease--should transurethral resection of the prostate be avoided? J Urol. 2009;181(5):2209–13.CrossRef
14.
Zurück zum Zitat Sakakibara R, Panicker J, Finazzi-Agro E, Iacovelli V, Bruschini H, Parkinson’s Disease Subcomittee, The Neurourology Promotion Committee in The International Continence Society. A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourol Urodyn. 2016;35(5):551–63.CrossRef Sakakibara R, Panicker J, Finazzi-Agro E, Iacovelli V, Bruschini H, Parkinson’s Disease Subcomittee, The Neurourology Promotion Committee in The International Continence Society. A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourol Urodyn. 2016;35(5):551–63.CrossRef
15.
Zurück zum Zitat Han HH, Ko WJ, Yoo TK, Oh TH, Kim DY, Kwon DD, et al. Factors associated with continuing medical therapy after transurethral resection of prostate. Urology. 2014;84(3):675–80.CrossRef Han HH, Ko WJ, Yoo TK, Oh TH, Kim DY, Kwon DD, et al. Factors associated with continuing medical therapy after transurethral resection of prostate. Urology. 2014;84(3):675–80.CrossRef
16.
Zurück zum Zitat Moisey CU, Rees RWM. Results of transurethral resection of prostate in patients with cerebrovascular disease. Br J Urol. 1978;50:539–41.PubMed Moisey CU, Rees RWM. Results of transurethral resection of prostate in patients with cerebrovascular disease. Br J Urol. 1978;50:539–41.PubMed
17.
Zurück zum Zitat Lum SK, Marshall VR. Results of prostatectomy in patients following a cerebrovascular accident. Br J Urol. 1982;54(2):186–9.CrossRef Lum SK, Marshall VR. Results of prostatectomy in patients following a cerebrovascular accident. Br J Urol. 1982;54(2):186–9.CrossRef
18.
Zurück zum Zitat Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86.CrossRef Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86.CrossRef
19.
Zurück zum Zitat Fjorback MV, Van Rey FS, Rijkhoff NJM, Nøhr M, Petersen T, Heesakkers JP. Electrical stimulation of sacral dermatomes in multiple sclerosis patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2007;26(4):525–30.CrossRef Fjorback MV, Van Rey FS, Rijkhoff NJM, Nøhr M, Petersen T, Heesakkers JP. Electrical stimulation of sacral dermatomes in multiple sclerosis patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2007;26(4):525–30.CrossRef
20.
Zurück zum Zitat Crayton H, Heyman RA, Rossman HS. A multimodal approach to managing the symptoms of multiple sclerosis. Neurology. 2004;63(11 Suppl 5):S12–8.CrossRef Crayton H, Heyman RA, Rossman HS. A multimodal approach to managing the symptoms of multiple sclerosis. Neurology. 2004;63(11 Suppl 5):S12–8.CrossRef
21.
Zurück zum Zitat Courtney AM, Castro-Borrero W, Davis SL, Frohman TC, Frohman EM. Functional treatments in multiple sclerosis. Curr Opin Neurol. 2011;24(3):250–4.CrossRef Courtney AM, Castro-Borrero W, Davis SL, Frohman TC, Frohman EM. Functional treatments in multiple sclerosis. Curr Opin Neurol. 2011;24(3):250–4.CrossRef
22.
Zurück zum Zitat Foster HE, Dahm P, Kohler TS, Lerner LB, Parsons JK, Wilt TJ, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline Amendment 2019. J Urol. 2019;202(3):592–8.CrossRef Foster HE, Dahm P, Kohler TS, Lerner LB, Parsons JK, Wilt TJ, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline Amendment 2019. J Urol. 2019;202(3):592–8.CrossRef
23.
Zurück zum Zitat Mitchell CR, Mynderse LA, Lightner DJ, Husmann DA, Krambeck AE. Efficacy of holmium laser enucleation of the prostate in patients with non-neurogenic impaired bladder contractility: results of a prospective trial. Urology. 2014;83(2):428–32.CrossRef Mitchell CR, Mynderse LA, Lightner DJ, Husmann DA, Krambeck AE. Efficacy of holmium laser enucleation of the prostate in patients with non-neurogenic impaired bladder contractility: results of a prospective trial. Urology. 2014;83(2):428–32.CrossRef
24.
Zurück zum Zitat Lomas DJ, Krambeck AE. Long-term efficacy of holmium laser enucleation of the prostate in patients with detrusor underactivity or acontractility. Urology. 2016;97:208–11.CrossRef Lomas DJ, Krambeck AE. Long-term efficacy of holmium laser enucleation of the prostate in patients with detrusor underactivity or acontractility. Urology. 2016;97:208–11.CrossRef
25.
Zurück zum Zitat Kavanagh A, Baverstock R, Campeau L, Carlson K, Cox A, Hickling D, et al. Canadian Urological Association guideline: diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction–full text. Can Urol Assoc J. 2019;13(6):E157–76.PubMedPubMedCentral Kavanagh A, Baverstock R, Campeau L, Carlson K, Cox A, Hickling D, et al. Canadian Urological Association guideline: diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction–full text. Can Urol Assoc J. 2019;13(6):E157–76.PubMedPubMedCentral
26.
Zurück zum Zitat •• Noordhoff TC, Groen J, Scheepe JR, BFM B. Surgical management of anatomic bladder outlet obstruction in males with neurogenic bladder dysfunction: a systematic review. Eur Urol Focus. 2019;5(5):875–86 This systematic review was unable to identify the optimal practice for surgical treatment of anatomic bladder outlet obstruction in males with neurogenic bladder dysfunction due to limited availability of high-quality studies.CrossRef •• Noordhoff TC, Groen J, Scheepe JR, BFM B. Surgical management of anatomic bladder outlet obstruction in males with neurogenic bladder dysfunction: a systematic review. Eur Urol Focus. 2019;5(5):875–86 This systematic review was unable to identify the optimal practice for surgical treatment of anatomic bladder outlet obstruction in males with neurogenic bladder dysfunction due to limited availability of high-quality studies.CrossRef
Metadaten
Titel
The Evidence For and Against Prostate-Reducing Procedures for Men with Neurogenic Bladder
verfasst von
Timothy M. Han
Patrick J. Shenot
Alex Uhr
Lydia Glick
Akhil K. Das
Publikationsdatum
14.11.2020
Verlag
Springer US
Erschienen in
Current Bladder Dysfunction Reports / Ausgabe 4/2020
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-020-00615-y

Weitere Artikel der Ausgabe 4/2020

Current Bladder Dysfunction Reports 4/2020 Zur Ausgabe

Inflammatory/Infectious Bladder Disorders (MS Mourad, Section Editor)

Hydatid Disease of the Urinary Bladder: a Review

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Management of Pelvic Floor Disorders in Young Women

Voiding Dysfunction Evaluation (B Brucker and B Peyronnet, Section Editors)

Assessing In Vivo Bladder Urothelial Hyper-Permeability: Preclinical and Clinical Implications

Global Health (Kurt McCammon, Section Editor)

Cost-Effectiveness and Economic Benefits of Volunteerism

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.